Logo

JP Morgan Healthcare Conference

Pierian, Seven Bridges, UgenTec Acquired, Merged to Become Velsera

The three firms were acquired by investment fund Summa Equity and merged to form a new Boston-headquartered company.

Element Biosciences Points to First Wave of Customer Data at JP Morgan Conference

The San Diego-based sequencing instrument maker highlighted data from three customers: the University of California, San Diego; Gencove; and Qiagen.

JP Morgan Healthcare Conference, Day 4: Singular Genomics, Quantum-Si, Quanterix

On the last day of the conference, Singular Genomics and Quantum-Si provided updates on their recently launched systems while Quanterix addressed its ongoing restructuring.

Rebranded GeneDx Bets Future on Whole-Exome, Whole-Genome Sequencing in Pediatric Rare Disease
Premium

After dropping underdeveloped Sema4 business lines but emphasizing the Centrellis informatics platform, the new GeneDx expects to reach profitability by 2025.

SomaLogic Seeks 'Strategic Alternatives' for Dx Business to Focus on Life Science Market

The proteomics firm is in talks to either spin off its SomaSignal assays unit or to partner with another company to boost its diagnostics efforts. 

Jan 12, 2023

JP Morgan Healthcare Conference, Day 3: Invitae, NanoString, Bio-Rad, Olink, More

Jan 12, 2023

Pacific Biosciences Provides Updates on Platforms, Contracts at JP Morgan Conference

Jan 11, 2023

Ginkgo Bioworks Expects to Meet 2022 Revenue Guidance Despite Foundry Services Shortfall

Jan 11, 2023

Evolving Akoya Biosciences Touts CDx Partnerships at JP Morgan Conference

Jan 11, 2023

JP Morgan Healthcare Conference, Day 2: Thermo Fisher, Agilent, Roche, Seer, More

Jan 11, 2023

Hologic Aims to Expand Global Reach With Focus on Women's Health

Jan 11, 2023

PerkinElmer Becoming Pure Play Dx, Life Science Firm, Spurred on by COVID Innovations

Jan 11, 2023

Natera Eyes Regulatory Path for Signatera as Companion Diagnostic

Jan 10, 2023

JP Morgan Healthcare Conference, Day 1: Guardant Health, Exact Sciences, Bruker, 10x Genomics, More

Jan 10, 2023

Myriad Genetics Highlights 2023 Product Launches for Women's Health, Oncology Businesses
Premium

Jan 10, 2023

Illumina Seeing Strong NovaSeq X Demand, Reports Preliminary Q4 Revenues Down 10 Percent

Jan 9, 2023

Qiagen Acquires Forensic Science NGS Firm Verogen for $150M

Jan 9, 2023

Preliminary Earnings Roundup: NanoString Technologies, SomaLogic, Pacific Biosciences, More

Jan 13, 2022

Pacific Biosciences Outlines Progress on Short-Read Sequencing at JPM, Partners With Canexia Health

Jan 13, 2022

NanoString Technologies Touts Interest in CosMx Spatial Biology Platform at JPM

Jan 13, 2022

Quanterix Projects Q4 2021 Revenues of $29M to $31M

Jan 13, 2022

JPM Healthcare Conference Day 3: Quantum-Si, Olink, Exact Sciences, Bio-Techne, Opko Health, More

Jan 13, 2022

Singular Genomics Outlines Launch Plans for G4 Sequencer at JPM

Jan 12, 2022

Invitae Launches Ciitizen Genome Information Management Platform at JPM

Jan 12, 2022

JPM Healthcare Conference Day 2: Thermo Fisher, BD, SomaLogic, Myriad, Oxford Nanopore, More

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.